Fluke Biomedical A.I CyberSecurity Scoring
18/12/2025
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Fluke Biomedical in 2026.
No incidents recorded for Fluke Biomedical in 2026.
No incidents recorded for Fluke Biomedical in 2026.
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
For nearly a century, we have delivered on our commitment to saving and sustaining the lives of patients, working alongside clinicians and providers around the world. We believe every person — regardless of who they are or where they are from — deserves a chance to live a healthy life, free from illness and full of possibility. At the intersection of progress and purpose is where we are redefining what it means to be a global medtech leader. It is where we are relentlessly pursuing healthcare transformation, fueled by our compassion for patients and providers and the challenges they face. It is where bold ideas meet the promise for meaningful change in the world around us. We are there, at every step of the journey, to help clinicians deliver the best care possible.
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We advance our mission to alleviate pain and improve the quality of life for patients around the world with our innovative products and suite of integrated digital and robotic technologies leverage data, data analytics and artificial intelligence. Founded in 1927 and based in Warsaw, Zimmer Biomet has operations in more than 25 countries and sales in more than 100 countries. We maintain world-class scientific facilities and resources and collaborate with leading clinicians and researchers around the world. Awards and Recognitions • Forbes: America's Best Companies 2026 • Workhuman: Luminary Award 2025 & Innovator Award 2024 • TIME: America's Best Companies [Mid-Size] 2024 • Great Place to Work - Best Workplaces: Switzerland & Poland 2025 • Great Place to Work Certified 2025 - 2026: USA, Poland, India, Colombia, Ireland, Puerto Rico, Kingdom of Saudi Arabia, Switzerland • MedTech: Breakthrough Award Best New Technology Solution in Orthopedics 2025 • Top Employers Institute: China 2025 • VETS Indexes: 4 Star Employer 2025
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. We partner with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life. Our global teams are pioneering what’s next across Life Sciences, Diagnostics, Biotechnology and beyond. For more information, visit www.danaher.com.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 34 countries and territories. The Company's sales reached $12.7 billion in 2024, and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.
We are dedicated to transforming lives by improving the journey to a healthy, beautiful smile. Discover your straight path to a bright future at Align Technology. As a part of our smart, diverse and fast-moving global team, you'll make an impact on the market leader that's moving an industry forward. Want to find out what's next for us—and for you? Follow us on LinkedIn for business updates and check out our current opportunities at www.aligntech.com/careers. 25 years ago, we pioneered the market for clear aligners. Since then, we have continuously innovated with new products and technologies that revolutionize treatments for doctors and their patients. Today, doctors and labs in over 100 markets use the Invisalign system, iTero intraoral scanners and exocad software to improve smiles for patients – from simple tooth alignment to complex corrections, kids to adults, orthodontics to multi-disciplinary restorative treatment. Learn more about Align Technology and our products: www.aligntech.com www.invisalign.com www.itero.com www.exocad.com
Olympus is passionate about creating customer-driven solutions for the medical industry. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 31,000 employees worldwide in nearly 40 countries and regions.
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com. See community guidelines here: bit.ly/4vTpKjz
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love to innovate and develop exciting technologies, and we offer competitive salaries and progressive benefits. But it’s our culture - of Care, Collaboration and Courage - that really sets us apart. Through a spirit of ownership and can-do attitude, we work together to win.. We’re a company of people who care about each other, about our customers and their patients, and about our communities. Together, we fulfill our shared purpose of Life Unlimited. Please note: not all products referred to may be approved for use or available in all markets.
Latest updates, reports, and threat intel affecting the global network.
A flaw has been found in sigoden aichat up to 0.30.4. This affects an unknown function of the file src/serve.rs of the component API Endpoint. This manipulation causes uncontrolled memory allocation. The attack can be initiated remotely. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.
A vulnerability was detected in rowboatlabs rowboat up to 0.9.1. The impacted element is the function request.text/req.json of the file apps/rowboat/app/api/composio/webhook/route.ts of the component Composio Webhook Endpoint. The manipulation results in denial of service. It is possible to launch the attack remotely. The exploit is now public and may be used. Upgrading to version 0.9.2 is sufficient to resolve this issue. Upgrading the affected component is recommended. The legacy Next.js app was deleted at 0.9.2 rather than patched, leaving no security control behind.
A security vulnerability has been detected in Reader Tools PDF Reader App 98.8 on Android. The affected element is the function ActSplashNew.handleDeeplink of the component File Handler. The manipulation of the argument _display_name leads to path traversal. An attack has to be approached locally. The exploit has been disclosed publicly and may be used. The vendor was contacted early about this disclosure but did not respond in any way.
Windows ML CLI is a command line tool for building portable, performant, and high-quality AI models for Windows ML. Prior to 0.4.0, the src/winml/modelkit/serve/cli_api.py component exposes WinML CLI commands through a localhost HTTP API without authentication and configures the allow_origins setting as a wildcard in both src/winml/modelkit/serve/cli_api.py and src/winml/modelkit/serve/app.py. A malicious website loaded by a user can send cross-origin requests to /v1/cli/build or /v1/cli/config and set the trust_remote_code parameter to true, which is converted to the --trust-remote-code command-line flag without validation. This reaches AutoConfig.from_pretrained with trust_remote_code=True in src/winml/modelkit/loader/_autoconfig.py and imports Python code from an attacker-controlled model repository, resulting in arbitrary code execution as the server user. This issue is fixed in version 0.4.0.
fast-uri serializes the port component of a URI without validating it. When recomposing the authority, the userinfo and host components are escaped but the port is concatenated verbatim, so a port value that is not a sequence of digits can inject authority delimiters, demoting the intended host to userinfo and pointing the authority at an attacker-controlled host. Both fast-uri and Node's URL read the result back as the attacker's host with no error, so re-validating the built URI does not catch it. This affects applications that build URIs from parts and assign untrusted data to the port component through the serialize, normalize, or equal functions in their object forms. The issue affects fast-uri versions before 2.4.6, from 3.0.0 before 3.1.7, and from 4.0.0 before 4.1.4. It is fixed in 2.4.6, 3.1.7, and 4.1.4, where recomposeAuthority rejects any port that is not a digit sequence per RFC 3986.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.